Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.3389/fendo.2013.00189</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879437">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879437</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://</td>
</tr>
</tbody>
</table>

Thrombospondin-1 silencing down-regulates integrin expression levels in human anaplastic thyroid cancer cells with BRAF<sup>V600E</sup>: new insights in the host tissue adaptation and homeostasis of tumor microenvironment

Mark Duquette<sup>1</sup>, Peter M. Sadow<sup>2</sup>, Jack Lawler<sup>3</sup> and Carmelo Nucera<sup>1</sup>*

<sup>1</sup> Human Thyroid Cancers Preclinical and Translational Research Laboratory, Division of Cancer Biology and Angiogenesis, Department of Pathology, Harvard Medical School, Boston, MA, USA
<sup>2</sup> Endocrine Service, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
<sup>3</sup> Division of Cancer Biology and Angiogenesis, Department of Pathology, Harvard Medical School, Center for Vascular Biology Research (CVBR), Beth Israel Deaconess Medical Center (BIDMC), Boston, MA, USA

*Correspondence:
Carmelo Nucera, Human Thyroid Cancers Preclinical and Translational Research Laboratory, Division of Cancer Biology and Angiogenesis, Department of Pathology, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA
E-mail: cnucera@bidmc.harvard.edu

Background and Rationale: Anaplastic thyroid cancer (ATC) is characterized by pleomorphic cells, has a poor prognosis, is highly devastating disease, and is not curable. No reliable biomarkers of metastatic potential, helpful for early diagnosis of ATC and therapeutic response have been found yet. Thrombospondin-1 (TSP-1) plays a fundamental role in cancer progression by regulating cell stromal cross-talk in the tumor microenvironment.

Goals: Our goal was to understand whether TSP-1 could affect protein levels of its integrin receptors (e.g., ITGa3, α6, and β1) and cell morphology in BRAF<sup>V600E</sup>-ATC cells in vitro and in vivo.

Experimental Design: Anaplastic thyroid cancer-derived cell cultures and western blotting were used to assess integrin protein expression upon TSP-1 silencing. Immunohistochemistry was performed on orthotopic primary human ATC and metastatic ATC in lung tissue to compare TSP-1 and integrin protein expression levels.

Results: TSP-1 knock-down down-regulates ITGa3, α6, and β1 in BRAF<sup>V600E</sup>-human ATC cells. BRAF<sup>V600E</sup>-ATC cells with TSP-1 knock-down were rounded compared to control cells, which displayed a spread morphology. TSP-1 knock-down also reduced TSP-1, ITGa3, α6, and β1 protein expression levels in vivo in the ATC microenvironment, which is enriched in stromal and inflammatory cells.

Conclusion: TSP-1 silencing causes changes in ITG levels and ATC cell morphology. The assessment of TSP-1 and ITG levels might contribute to earlier metastatic potential of BRAF<sup>V600E</sup>-positive aggressive thyroid cancers, and allow improved patient selection for clinical trials.

Keywords: BRAF<sup>V600E</sup>, integrins, thyroid cancer, microenvironment, extracellular matrix, TSP-1
matrix proteins [i.e., Fibronectin (FN)], cytokines (i.e., TGF-β1), pro-angiogenic factors (e.g., VEGF), and matrix proteases (i.e., MMP-9), indicating its importance in cross-talk between ECM molecules and their receptors (11, 12). Also, TSP-1 is involved in tumor cell adhesion and migration, and it may direct clustering of receptors to specialized domains for these biological processes (10). Integrins are a family of cell surface glycoproteins that function as receptors for ECM proteins, mediating both cell–cell and cell–ECM adhesion. Integrins are non-covalent, heterodimeric complexes of an alpha (α) and a beta (β) subunit (13). Their role is fundamental in cell microenvironment homeostasis, including either physiological or pathological conditions. Whereas, the role of TSP-1 in angiogenesis is well documented, its role in tumor metastasis is only just emerging. TSP-1 has been shown to promote metastasis in a breast cancer model (14). Our previous study has shown that the N-terminal domain of TSP-1 is involved in BRAF<sub>V600E</sub>-mediated invasion in thyroid cancer cells (5). Chandrasekaran et al. (10) also showed a critical role for the TSP-1 N-terminal domain in breast cancer cell invasion via putative binding site(s) to ITGβ3/ITGβ1, which has an important role in tumor cell migration and invasion. Sumimoto et al. (15) have shown that BRAF<sub>V600E</sub> knock-down decreased phospho-ERK1/2 protein levels and inhibited invasion of melanoma cells accompanied by a decrease of matrix metalloproteinase activity and ITGβ1 expression. Dynamic and reciprocal interactions involving cell adhesion molecules (e.g., integrins, CD44), ECM non-cellular components (i.e., TSP-1, FN), and soluble cytokines occur between tumor epithelial cells and tumor microenvironment stromal cells (13). Importantly, TSP-1 could be a valid biomarker for PTC aggressiveness and we have already established an immunohistochemistry (IHC)-based screening assay suitable for clinical trials (5). The goal of this brief research article is to understand whether TSP-1 affects integrin levels and cell morphology in BRAF<sub>V600E</sub>-positive ATC cells, contributing to metastasis.

MATERIALS AND METHODS

CELL CULTURE

The SW1736 ATC cell line, which harbors heterozygous BRAF<sub>WT/V600E</sub>, was kindly provided by N. E. Heldin (University of Uppsala, Uppsala, Sweden). The 8505c ATC cell line homozygous for BRAF<sub>V600E</sub> was purchased from DSMZ (German collection of microorganisms and cell culture) (Braunschweig, Germany). The 8505c cell line was established by Dr. M. Akiyama (Radiation Effects Research Foundation, Hiroshima, Japan) from the primary tumor of a 78-year-old woman with undifferentiated carcinoma. It is histologically an ATC with some spindle, polygonal, and giant cells (data by DSMZ). SW1736 and 8505c cell lines were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin/streptomycin/amphotericin.

ANTIBODIES

Antibodies against the following proteins were used: β-actin (A-5316) (Sigma); TSP-1 (A6.1) for IHC (Abcam, USA), and the previously validated TSP-1 clone MA-I for Western blot (5, 16) and R1 for immunofluorescence (17, 18); anti-ITGα3 (C-18, Santa Cruz Biotechnology, USA), anti-ITGα6 (H-87, Santa Cruz Biotechnology, USA), and anti-ITGβ1 (kindly provided from Dr. Richard Hynes, MIT, Cambridge, MA, USA); anti-phospho-FAK (cat. #3283, Cell Signaling, USA), and anti-total FAK (cat #3285, Cell Signaling, USA). CD45 (cat #550539, BD Pharmingen, USA), F4-80 (cat #14-4801, eBioscience, USA), and αSMA (alpha-smooth muscle actin) (A2547, Sigma, USA).

CELL TRANSFECTIONS FOR LENTIVIRUS PRODUCTION

HEK 293T cells (5 × 10<sup>6</sup>) were grown in 60-mm plates and transduced using Fugene-6 (Roche) in OptiMEM (Invitrogen) for 48 h according to the manufacturer’s instructions.

TSP-1 SILENCING TECHNIQUES

Stable transduced [shRNA (sh) viral transductions] ATC cells with or without TSP-1 knock-down were established according to Nucera et al. (5).

WESTERN BLOT

Western blotting assays were performed following standard protocols; cells were lysed in buffer, composed of 10 mM HEPES (pH 7.40), 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1 mM sodium vanadate, 5 mM sodium fluoride, and 1% Triton-X 100; protease and phosphatase inhibitors (Pierce) were used for protein extractions (5).

IN Vivo STUDIES

The animal work was done in the animal facility at Beth Israel Deaconess Medical Center (Boston, MA, USA) in accordance with federal, local, and institutional guidelines. We used an orthotopic mouse model of ATC as previously described and validated by Nucera et al. (19) (5), using female about 6-week-old severe combined immunodeficient (SCID) mice (Taconic, USA).

HISTOLOGY AND IMMUNOHISTOCHEMISTRY

All tissue specimens (five primary orthotopic ATC or lung specimens from mice with sh-control TSP-1 8505c cells; and five primary orthotopic ATC or lung specimens from mice with sh-TSP-1 knock-down 8505 cells) were fixed with 10% buffered formalin and embedded in paraffin blocks. Histopathology evaluation was performed by a pathologist (Peter M. Sadow) on hematoxylin and eosin-stained tissue sections of orthotopic 8505c ATC specimens (5). All photos were captured with an Olympus BX41 microscope and the Olympus Q COLOR 5 photo camera (Olympus Corp., Lake Success, NY, USA), using the Twain software in Adobe Photoshop (7.0) and white balanced with the same method for all images. Sections (4 μm thick) of formalin-fixed orthotopic 8505c ATC specimens (5) were used for IHC procedures. After baking overnight at 37°C, deparaffinization with xylene/ethanol and rehydration were performed. IHC analysis was performed using primary antibodies against human TSP-1 (1:25, citrate buffer for antigen retrieval), ITGα3 (1:250, citrate buffer for antigen retrieval), ITGα6 (1:200, citrate buffer for antigen retrieval), or ITGβ1 (1:500, citrate buffer for antigen retrieval); anti-mouse CD45 antibody (#550539, BD Pharmingen, USA); 1:50, citrate buffer and pressure cooker for antigen retrieval; anti-mouse F4-80 antibody (pan macrophage marker) (#144801, eBioscience, USA); 1:50, citrate buffer and pressure cooker for antigen retrieval; and anti-mouse alpha-smooth muscle actin (αSMA) (#A-2547, Sigma, USA) (1:20,000). The sections, treated with pressure cooker for antigen retrieval (Biocare Medical, Concord,
CA, USA), were incubated at 123°C in citrate buffer (Dako Target Retrieval Solution, S1699; DAKO Corp.), cooled and washed with PBS. Antigen retrieval was performed for 60 min at room temperature. The primary antibody was detected using a biotin-free secondary antibody (K4011) (Dako Envision system) and incubated for 30 min. All incubations were carried out in a humid chamber at room temperature. Slides were rinsed with PBS between incubations. Sections were developed using 3,3-diaminobenzidine (Sigma Chemical Co.) as a substrate and were counterstained with Mayer’s hematoxylin. PAX8 and p53 immunostaining was performed according to our previous study (19). We used species-specific IgG as negative control. The IHC markers were assessed semiquantitatively using the following scoring method: 0 negative, 1 1–10% positive cells (low expression), 2 11–50% positive cells (moderate), and 3 more than 50% positive cells (high expression) according to Shaik et al. (20).

IMMUNOFUORESCENCE

For immunofluorescence experiments, $5 \times 10^4$ 8505c or SW1736 cells were seeded on type I collagen-coated cover slips (BD Biosciences) for 24 h. Cells were washed three times with PBS, fixed with 4% paraformaldehyde for 10 min at room temperature, and permeabilized with PBS 0.5% Triton-X 100 for 5 min at room temperature. After three washes with PBS, cells were blocked with TBST 1% BSA for 20 min, followed by incubation with phalloidin-fluorescein (Sigma, USA) in PBST 1% BSA for 30 min at room temperature. Cells were rinsed three times with TBS. Finally, the cover slips were mounted with a mixture of Vectashield mounting medium and DAPI (Vector Laboratories). Cells were imaged at 20× on a Nikon Eclipse 300 epifluorescence inverted microscope connected to a Retiga 2000RV camera (Nikon Instruments).

STATISTICAL ANALYSIS

Statistical analysis was carried out using Microsoft Excel Software. Results were compared using the Student’s t-test and $\chi^2$ test. P values of <0.05 were considered significant (*P < 0.05, **P < 0.01, ***P < 0.001). Densitometry analysis was performed using Quantity One software (BioRad, USA).

RESULTS

KNOCK-DOWN OF TSP-1 DOWN-REGULATES INTEGRINS LEVELS AND AFFECTS CELL MORPHOLOGY IN HUMAN ANAPLASTIC THYROID CANCER CELLS WITH BRAF$^{V600E}$

Our results show that ITGα3 (~95%), ITGα6 (~95%), and ITGβ1 (~90%) subunits are decreased in homozygous BRAF$^{V600E}$-positive 8505c ATC cells with TSP-1 knock-down (Figure 1). Furthermore, either homozygous BRAF$^{V600E}$-positive 8505c ATC cells or heterozygous BRAF$^{V600E}$-positive SW1736 ATC cells with TSP-1 knock-down display a markedly different morphology (rounded cells) compared to sh-controls cells (spread morphology) when plated on type 1 collagen (Figure 2). We also found

![Figure 1](image-url)
that TSP-1 knock-down by shRNA (sh) caused a down-regulation of pFAK protein levels (∼90%) in human thyroid cancer cells with homozygous BRAF$^{V600E}$ (Figure 1).

**TSP-1 KNOCK-DOWN DOWN-REGULATES INTEGRINS LEVELS IN THE ORTHOTOPIc BRAF$^{V600E}$ METASTATIC 8505c ATC CELLS IN VIVO**

The orthotopic human BRAF$^{V600E}$-positive 8505c ATC microenvironment *in vivo* shows stromal cells, identified by expression of some marker proteins: CD45+ (lymphocytic lineage), F4/80+ (macrophages) (21, 22), and αSMA+ (spindle-shaped pericytes) (23) (Figure 3).

The 8505c cells with TSP-1 knock-down metastasize less (5) and show very low protein levels of (i) ITGα3 [from 10 ITGα3-positive cells (score 2) in the sh-control 8505 orthotopic tumors to 2 cells ± 0.5/field in the sh-TSP-1 8505c orthotopic tumors; score: 1+, $P < 0.05$]; (ii) ITGα6 [from 16 ITGα6-positive cells (score 2) in the sh-control 8505 orthotopic tumors to 3 cells ± 0.35/field; score: 1+, $P < 0.05$]; and (iii) ITGβ1 [from 12 ITGβ1-positive cells (score 2) in the sh-control 8505 orthotopic tumors to 2 cells ± 0.42/field; score: 1, $P < 0.05$] in the primary orthotopic 8505c ATC (Figures 4A,B), as well as in the lungs (Figure 4C) where generally 8505c ATC cells preferentially metastasize (19). IHC staining in the TSP-1 knock-down condition (Figure 4C) highlights TSP-1 and integrin protein expression in macrophages (noted by the dot-like, granular cytoplasmic staining, and bland histomorphology) but not in the metastatic 8505c cells. Additionally, lung tissue from the 8505c ATC orthotopic mice with TSP-1 knock-down was also completely negative for both PAX8 and p53 protein expression that show prominent nuclear staining in 8505c cells which were absent (data not shown) (19). Furthermore, we have also found that TSP-1 [3 cells positive/field (score 2)], ITGα3 [6 cells positive/field (score 2)], and ITGβ1 [2 cells positive/field...
Figure 3 | Stromal cells in the orthotopic 8505c human anaplastic thyroid cancer (ATC) microenvironment of SCID immunocompromised mice (400× magnification, representative of eight mice). About 2% of cells/field were of lymphocytic lineage (CD45, localized to plasma membrane); ~8% were identified as macrophages [F4/80 (pan macrophage marker), localized to plasma membrane]; and ~5% were spindle-shaped pericytes, identified by staining for cytosolic αSMA (alpha-smooth muscle actin).

(score 1) proteins were expressed in the metastatic 8505c cells in the lungs but not up-regulated compared to their expression in the primary orthotopic 8505c human ATC cells (Figure 4), thus suggesting that the potential intravasation and colonization of ATC cells do not up-regulate the basal protein expression levels of TSP-1, ITGα3, and ITGβ1, which might be sufficient to trigger metastasis. By contrast, we found that ITGα6 protein expression levels [2 cells positive/field (score 2)] were up-regulated in the orthotopic metastatic 8505c ATC cells in the lungs compared to the primary orthotopic 8505c ATC cells in the mouse thyroid.

DISCUSSION
Thyroid carcinomas are increasing in frequency and account for 2.5% of all cancers in the United States (USA). ATC is a devastating disease with low survival rate due to uncontrolled systemic metastasis and with no effective treatment options. ATC represents 1.7% of all human thyroid cancers in USA, and geographically its prevalence ranges from 1.3 to 9.8% (median = 3.6%) (3). Conventional ATC therapy currently utilizes a multimodal approach using radiation therapy and chemotherapeutic agents such as doxorubicin. The local disease burden often is so extensive that surgery is confined to tumor debulking and securing the airway. Additionally, no reliable biomarkers of metastatic potential, helpful for early diagnosis of ATC and therapeutic response have been found yet.

ATC shows a pleomorphic and interconnected network between high-grade malignant cells and stromal cells (e.g., macrophages) that characterize tumor microenvironment (24). Here our results from an in vivo orthotopic mouse model of human ATC also suggest that the ATC microenvironment is enriched in stromal cells, including macrophages, leukocytes, endothelial cells, and pericytes, which might contribute to the ATC aggressiveness.

Changes in the tumor microenvironment (e.g., deregulation of ECM molecules or ECM receptors) are a critical step in human cancer invasion, metastasis, and progression. We found that TSP-1 (a key player for ECM remodeling) and integrins (ECM receptors) are associated with BRAFV600E-positive PTC
We also showed that BRAF V600E or TSP-1 knock-down down-regulated ERK1/2 phosphorylation protein levels and inhibited ATC cell proliferation, adhesion, migration, and invasion (9, 13). It has been proposed that both pro-metastatic and anti-metastatic properties (14, 29). TSP-1 in the mammary tumor microenvironment inhibits angiogenesis and breast cancer growth, but promotes metastasis to the lung in a transgenic model of breast cancer (14). The ability of TSP-1 to support metastasis correlates with its ability to promote tumor cell migration (14).

Integrins are TSP-1 receptors that mediate tumor cell-ECM adhesion and provide both the connection to the adhesive substrate and cellular signaling crucial for cell proliferation, migration, and invasion (9, 13). To our best knowledge, this is the first report that shows that TSP-1 affects protein levels of integrins in BRAF V600E-positive human ATC cells in vitro and in vivo. Also, TSP-1 knock-down per se significantly alters ATC cell morphology on type 1 collagen. Collectively, our results may suggest that BRAF V600E ATC cells might acquire an adaptation in the host tissue during their tissue colonization, reprogram their gene expression profile and up-regulate integrin (i.e., ITGα6) protein levels. This observation is supported from a recent report that shows that TSP-1 stimulates ITGα6 protein expression levels in human breast carcinoma cells, promoting tumor cell adhesion and invasion (9).

Additionally, the missense SNP rs11895564 (Ala380Thr) in ITGα6 protein levels and ATC cell morphology. Therapeutic strategies aimed at modulating the thyroid cancer microenvironment might provide an additional perspective for the treatment of patients with these types of cancers. Routine assessment of pro-metastatic biomarkers, including TSP-1 and integrins, will help monitor patients undergoing targeted therapies, enable earlier metastatic potential of aggressive BRAF V600E-positive human thyroid cancer, foster development of innovative therapies for refractory thyroid cancer.
to current treatments, and allow improved patient selection for clinical trials.

ACKNOWLEDGMENTS

This work was supported by grants to Carmelo Nucera (Principal Investigator, Program: Human Thyroid Cancers Preclinical and Translational Research) funded by the National Institutes of Health Grants NIHIR21CA165039 (to Carmelo Nucera) and the American Thyroid Association (AFA) for the Thyroid Cancer Research Grant. Carmelo Nucera was also recipient of the Guido Berlucchi research award (Brescia, Italy). This work is also supported by CA130895 (to Jack Lawler). We thank Dr. Yutaka Kawakami (Keio University, Tokyo, Japan) for providing HIV-VEGF vectors. We also thank Nina Hu, Monique V. Bowford, and James Lawler (summer students at the Beth Israel Deaconess Medical Center).

REFERENCES

3. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. Ameri-

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 15 October 2013; accepted: 20 November 2013; published online: 02 December 2013.
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology.

Copyright © 2013 Duquette, Sadow, Lawler and Nucera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.